<DOC>
	<DOCNO>NCT00006187</DOCNO>
	<brief_summary>This 15-month study two phase . During first 12-month phase study , patient randomly assign receive either active study drug placebo ( approximately half patient active study drug , half placebo ) . The second phase 3-month randomized withdrawal period . For phase approximately 10 % patient remain active drug .</brief_summary>
	<brief_title>The Safety Efficacy Investigational Drug Delaying Progression Alzheimer 's Disease</brief_title>
	<detailed_description>This placebo-controlled , parallel-groups , 12 month , double-blind study , follow 3-month , double-blind , randomized withdrawal period evaluate efficacy safety investigational drug ( currently approve indication ) slow progression symptom AD . Patients probable AD accord NINCDS-ADRDA criterion Mini Mental State Examination ( MMSE ) score 13 26 inclusive eligible participation study . Patients stable dos market cholinesterase inhibitor approve treatment AD ( except tacrine ) least 3 month eligible study entry . Use NSAIDs ( except aspirin 81 mg per day ) allow study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient male female least 50 year age old Female patient must postmenopausal surgically sterilize Clinical diagnosis AD Patient must good health except AD diagnosis Patient must informant/caregiver monitor assist patient study Patient live nursing home skilled nursing facility Women ineligible postmenopausal surgically sterilize Site physician Sponsor may exclude patient serious medical problem cancer , cardiovascular disease , major neurological psychiatric illness , thyroid disease , major head trauma</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Investigational Drug</keyword>
</DOC>